Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Usana Health Sciences (USNA) EBIAT (2016 - 2026)

Usana Health Sciences has reported EBIAT over the past 17 years, most recently at $7.5 million for Q2 2026.

  • Quarterly EBIAT fell 20.07% to $7.5 million in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $8.2 million through Apr 2026, down 76.53% year-over-year, with the annual reading at $10.8 million for FY2026, 74.42% down from the prior year.
  • EBIAT was $7.5 million for Q2 2026 at Usana Health Sciences, up from -$2.3 million in the prior quarter.
  • Over five years, EBIAT peaked at $31.5 million in Q1 2022 and troughed at -$6.7 million in Q3 2025.
  • The 5-year median for EBIAT is $12.1 million (2022), against an average of $12.5 million.
  • Year-over-year, EBIAT skyrocketed 31.04% in 2023 and then plummeted 162.81% in 2025.
  • A 5-year view of EBIAT shows it stood at $12.8 million in 2022, then surged by 31.04% to $16.8 million in 2023, then crashed by 73.26% to $4.5 million in 2024, then plummeted by 248.57% to -$6.7 million in 2025, then soared by 212.8% to $7.5 million in 2026.
  • Per Business Quant, the three most recent readings for USNA's EBIAT are $7.5 million (Q2 2026), -$2.3 million (Q1 2026), and -$6.7 million (Q3 2025).